The Future of Biofilm Mitigation

Advanced micro-perforation technology engineered for dental aligners and retainers. Enhancing Air Exchange Rates to actively combat oral pathogens.

Explore the Science

Design & Functionality

Aeretainer Orthogonal Patent Drawings

Orthogonal Patent Drawings

Detailed views outlining the Structural Integrity Zone and the precise micro-perforation matrix.

Passive Air Exchange Simulation

Demonstrating continuous airflow and biofilm inhibition.

Core Innovations

Optimized Aeration Rate (AER)

Engineered to facilitate passive air exchange, achieving an AER of at least 3.0 Air Changes per Hour (ACH) to create a hostile microenvironment for Streptococcus mutans and Candida albicans.

Structural Integrity Zone

A calculated matrix mapping ensures occlusal and incisal edges remain solid, preserving mechanical durability while maximizing the perforation area across the labial surface.

Automated CNC Micro-Perforation

Utilizing precision laser ablation logic and adaptive 3D printing parameters for a high-density, staggered grid pattern that does not compromise patient comfort.

Patent & Research Status

Global Intellectual Property

Aeretainer technology is fully patent-pending across multiple jurisdictions to protect the proprietary micro-perforation mapping and structural logic.

  • USA: App No. 19/698,887
  • Canada: App No. 3,292,200

AI-Driven Perforation Mapping

In Development: Integration of deep learning algorithms to auto-generate patient-specific perforation matrices based on individual dental topography and saliva flow dynamics.

Clinical Evaluations

Upcoming Phase: Initiating B2B partnership evaluations under strict NDA frameworks to validate biofilm mitigation efficacy in long-term orthodontic wear.

Leadership Team

Aeretainer is developed by the executive research and engineering division of Vaxx Research Incorporated.

Paul Hallelujah

Paul Hallelujah

CEO & Inventor

Mohamed Al Jalanji

Mohamed Al Jalanji

Lead AI Architect

Partner With Us

For licensing inquiries, clinical trial participation, or investment opportunities.

Email: [email protected]